These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 32915420)

  • 21. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.
    Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF
    Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
    Gambacorti-Passerini C; Orlov S; Zhang L; Braiteh F; Huang H; Esaki T; Horibe K; Ahn JS; Beck JT; Edenfield WJ; Shi Y; Taylor M; Tamura K; Van Tine BA; Wu SJ; Paolini J; Selaru P; Kim TM
    Am J Hematol; 2018 May; 93(5):607-614. PubMed ID: 29352732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
    Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
    Zhao S; Liu W; Li S; Shi T; Chen Q; Li Q; Sun L; Ren D; Song Z; Huang C; Xu S
    Cancer Res Treat; 2021 Apr; 53(2):601-606. PubMed ID: 33091968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
    Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
    Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.
    Debonis SA; Bongiovanni A; Pieri F; Fausti V; De Vita A; Riva N; Gurrieri L; Vanni S; Diano D; Mercatali L; Ibrahim T
    Medicine (Baltimore); 2021 May; 100(20):e25972. PubMed ID: 34011083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
    Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
    Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
    Lim JJ; Chen EY; Schaub SK; Wagner MJ
    Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancers.
    Jerry L; Swan L; Dana N; Balis FM; Greengard E; Huiping X
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31139. PubMed ID: 38867367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory myofibroblastic tumor arising from soft tissues of extremities harboring a novel CLIP2-ALK fusion.
    Ding R; Li X; Zhu XM; Song QX; Fan QH; Zhang ZH; Gong QX
    Pathol Int; 2020 Oct; 70(10):798-803. PubMed ID: 32716129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.
    Chmiel P; SłOWIKOWSKA A; Banaszek Ł; Szumera-CIEćKIEWICZ A; Szostakowski B; SPAłEK MJ; Świtaj T; Rutkowski P; Czarnecka AM
    Oncol Res; 2024; 32(7):1141-1162. PubMed ID: 38948020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recurrent inflammatory myofibroblastic tumor patient with two novel
    Xu X; Li L; Zhang Y; Meng F; Xie H; Duan R
    Transl Cancer Res; 2022 Sep; 11(9):3379-3384. PubMed ID: 36237256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
    Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
    Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
    Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
    Front Oncol; 2022; 12():761558. PubMed ID: 35237506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
    Zhang P; Wang C; Lv Z; Du M; Xu R
    J Cardiothorac Surg; 2023 Nov; 18(1):318. PubMed ID: 37950305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.